23andMe laying off 14% of employees amid slump in DNA spit kit sales
NATHAN SIEMERS/CREATIVE COMMONS
In the coming months, 23andMe will focus on furthering its drug development pipeline, along with boosting sales of its at-home test kits.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario